Ikena Oncology (NASDAQ:IKNA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ikena Oncology (NASDAQ:IKNA) in a report published on Monday morning, Benzinga reports. They currently have a $4.00 target price on the stock.

Separately, Wedbush cut shares of Ikena Oncology from an outperform rating to a neutral rating and decreased their price objective for the stock from $8.00 to $2.00 in a research report on Wednesday, May 29th.

Ikena Oncology Price Performance

Shares of IKNA opened at $1.67 on Monday. The business has a 50-day moving average of $1.68 and a 200-day moving average of $1.50. The company has a market capitalization of $80.59 million, a price-to-earnings ratio of -1.06 and a beta of 0.48. Ikena Oncology has a 1 year low of $1.02 and a 1 year high of $5.21.

Ikena Oncology (NASDAQ:IKNA) last released its earnings results on Monday, May 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.12. As a group, sell-side analysts anticipate that Ikena Oncology will post -1.22 EPS for the current year.

Institutional Investors Weigh In On Ikena Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $30,000. BBR Partners LLC acquired a new position in shares of Ikena Oncology during the second quarter valued at about $33,000. SG Americas Securities LLC boosted its position in shares of Ikena Oncology by 88.5% during the 4th quarter. SG Americas Securities LLC now owns 20,222 shares of the company’s stock worth $40,000 after purchasing an additional 9,495 shares in the last quarter. JBF Capital Inc. acquired a new stake in Ikena Oncology in the second quarter valued at approximately $120,000. Finally, Marquette Asset Management LLC acquired a new position in Ikena Oncology during the first quarter worth $104,000. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.